Table I.
Inhibitor | Protease
Activity
|
Oxidative Burst
|
||
---|---|---|---|---|
Inhibitor concentration | Protease activity | Control | Yeast elicitor | |
μm | % | μm H2O2 | ||
Control (DMSO) | 0 | 100 | 0.00 ± 0.10 | 2.10 ± 0.44 |
Antipain | 20 | 0 | 4.55 ± 0.43 | 13.2 ± 1.17 |
DCIa | 1000 | 26 | 1.03 ± 0.27 | 12.4 ± 1.49 |
DFP | 1000 | 2 | 1.34 ± 0.17 | 9.46 ± 1.03 |
Leupeptin | 15 | 0 | 0.13 ± 0.11 | 5.90 ± 0.34 |
PMSF | 1000 | 81 | 0.11 ± 0.06 | 12.4 ± 1.41 |
TLCKb | 1000 | 61 | 0.10 ± 0.13 | 3.52 ± 0.22 |
TPCKc | 1000 | 47 | 5.86 ± 0.60 | 8.90 ± 1.07 |
Concentrations of inhibitors used in vitro are given. Inhibitors were applied to cells at a final concentration of 0.5 mm (0.2 mm for antipain), and H2O2 was measured 2 h after exposure to water (control) or yeast elicitor (200 μg Glc equivalents mL−1). Results show the average ± sd from three independent experiments.
DCI, 3,4-dichloroisocoumarin.
TLCK, Nα-p-tosyl-l-lysine chloromethyl ketone.
TPCK, n-tosyl-l-phenylalanine chloromethyl ketone.